Boston, MA -- (SBWIRE) -- 12/05/2014 -- The Japanese pharmaceutical market continues to hold strong rewards for innovative pharmaceutical companies. This is driven by the country's rapidly ageing population, preference for branded medicines and strong public coverage of drug expenditure. However, the cost containment measures by the government including aggressively cutting medicine prices pose a downward risk to the market's long term growth.

Risk/Reward Index

Japan's Pharmaceutical Risk/Reward Index (RRI) score for Q115 increased to 78.1 out of the maximum 100 in our newly improved RRR system. This high score makes Japan the most attractive country in comparison with the other 18 key Asia Pacific markets, followed by South Korea (68.6) and Australia (67.0). Japan's score is boosted by the large multi-billion dollar drug market (market expenditure score of 18.0 out of 20) and large pensionable population (pensionable population score of 8.0 out of 8), but dragged down by a declining pharmaceutical market (sector value growth score of 3.6 out of 12) and a declining population (population growth score of 1.0 out of 5). Thus, Japan's ageing population will translate into increased pharmaceutical sales although with relatively low growth prospects over the long term.

View Full Report Details and Table of Contents

BMI Economic View: The monetary stimulus measure employed over the past 18 months appear to have worked their way through the economy to a large extent, and the prospects of a self-sustaining recovery are diminishing. The collapse in wage growth is a particularly telling sign, and we continue to forecast real GDP growth of just 0.9% and 0.8% in 2014 and 2015, versus consensus expectations of 1.5% and 1.2% respectively.

BMI Political View: Prime Minister Shinzo Abe will be prevented from enacting his preferred economic reforms, due to rising opposition from within his ruling Liberal Democratic Party (LDP) and its New Komeito coalition partner. As with Abe's attempts at fiscal reform, the premier will also find his...

The Japan Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Japan Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Japanese pharmaceutical and healthcare industry.

Key Benefits:

- Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Japan to test other views - a key input for successful budgeting and strategic business planning in the Japanese pharmaceutical and healthcare market.

- Target business opportunities and risks in the Japanese pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Japan.

- Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 800-844-8156

Browse all Healthcare research reports at Fast Market Research

You may also be interested in these related reports:

- Turkey Pharmaceuticals & Healthcare Report Q1 2015
- Slovenia Pharmaceuticals & Healthcare Report Q1 2015
- Thailand Pharmaceuticals & Healthcare Report Q1 2015
- Kenya Pharmaceuticals & Healthcare Report Q1 2015
- Ukraine Pharmaceuticals & Healthcare Report Q1 2015
- Jordan Pharmaceuticals & Healthcare Report Q1 2015
- Argentina Pharmaceuticals & Healthcare Report Q1 2015
- Hong Kong Pharmaceuticals & Healthcare Report Q1 2015
- Croatia Pharmaceuticals & Healthcare Report Q1 2015
- Singapore Pharmaceuticals & Healthcare Report Q1 2015